PLURIPOTENT STEM CELL THAT INDUCES REPAIR AND REGENERATION AFTER MYOCARDIAL INFARCTION
First Claim
1. A method of treating myocardial infarction in a subject in need thereof, the method comprising:
- administering to said subject a cell preparation comprising concentrated pluripotent stem cells positive for SSEA-3, wherein the pluripotent stem cells are obtained from a mesenchymal cell population derived from mesenchymal tissue or cultured mesenchymal cells, wherein said pluripotent stem cells have been purified by SSEA-3 positive or concentrated by external stress stimulation, to thereby treat the myocardial infarction, and wherein the pluripotent stem cells have a plurality of properties comprising;
(i) CD105-positivity;
(ii) low or absent telomerase activity;
(iii) ability to differentiate into embryonic endoderm, ectoderm, and mesoderm germ layers;
(iv) absence of demonstration of neoplastic proliferation; and
, (v) ability to self-renewal.
5 Assignments
0 Petitions
Accused Products
Abstract
An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
-
Citations
13 Claims
-
1. A method of treating myocardial infarction in a subject in need thereof, the method comprising:
administering to said subject a cell preparation comprising concentrated pluripotent stem cells positive for SSEA-3, wherein the pluripotent stem cells are obtained from a mesenchymal cell population derived from mesenchymal tissue or cultured mesenchymal cells, wherein said pluripotent stem cells have been purified by SSEA-3 positive or concentrated by external stress stimulation, to thereby treat the myocardial infarction, and wherein the pluripotent stem cells have a plurality of properties comprising;
(i) CD105-positivity;
(ii) low or absent telomerase activity;
(iii) ability to differentiate into embryonic endoderm, ectoderm, and mesoderm germ layers;
(iv) absence of demonstration of neoplastic proliferation; and
, (v) ability to self-renewal.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
Specification